A population-based study of the drug interaction between proton pump inhibitors and clopidogrel
Abstract
Background: Most proton pump inhibitors inhibit the bioactivation of clopidogrel to its active metabolite. The clinical significance of this drug interaction is unknown.
Methods: We conducted a population-based nested case–control study among patients aged 66 years or older who commenced clopidogrel between Apr. 1, 2002, and Dec. 31, 2007, following hospital discharge after treatment of acute myocardial infarction. The cases in our study were those readmitted with acute myocardial infarction within 90 days after discharge. We performed a secondary analysis considering events within 1 year. Event-free controls (at a ratio of 3:1) were matched to cases on age, percutaneous coronary intervention and a validated risk score. We categorized exposure to proton pump inhibitors before the index date as current (within 30 days), previous (31–90 days) or remote (91–180 days).
Results: Among 13 636 patients prescribed clopidogrel following acute myocardial infarction, we identified 734 cases readmitted with myocardial infarction and 2057 controls. After extensive multivariable adjustment, current use of proton pump inhibitors was associated with an increased risk of reinfarction (adjusted odds ratio [OR] 1.27, 95% confidence interval [CI] 1.03–1.57). We found no association with more distant exposure to proton pump inhibitors or in multiple sensitivity analyses. In a stratified analysis, pantoprazole, which does not inhibit cytochrome P450 2C19, had no association with readmission for myocardial infarction (adjusted OR 1.02, 95% CI 0.70–1.47).
Interpretation: Among patients receiving clopidogrel following acute myocardial infarction, concomitant therapy with proton pump inhibitors other than pantoprazole was associated with a loss of the beneficial effects of clopidogrel and an increased risk of reinfarction.
In this issue
Article tools
Jump to section
Related Articles
Cited By...
- Association of direct oral anticoagulant-proton pump inhibitor cotherapy with adverse outcomes: protocol for a population-based cohort study
- Prescription of proton pump inhibitors in older adults with complex polytherapy
- Are proton pump inhibitors among the risk factors for acute coronary syndrome?: A multi-centric case-control study between patients attending governmental hospitals in western Saudi Arabia
- Comparative risk of new-onset diabetes following commencement of antipsychotics in New Zealand: a population-based clustered multiple baseline time series design
- Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program
- Triple antithrombotic therapy for atrial fibrillation and coronary stents
- Tritherapie antithrombotique pour la fibrillation auriculaire et les endoprotheses coronariennes
- Dual antiplatelet therapy for secondary stroke prevention: Use of clopidogrel and acetylsalicylic acid after noncardioembolic ischemic stroke
- Potential harms of proton pump inhibitor therapy: rare adverse effects of commonly used drugs
- Trends in the coprescription of proton pump inhibitors with clopidogrel: an ecological analysis
- Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study
- Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis
- Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity
- Conflicting Results Between Randomized Trials and Observational Studies on the Impact of Proton Pump Inhibitors on Cardiovascular Events When Coadministered With Dual Antiplatelet Therapy: Systematic Review
- Recent advances in antithrombotic therapy after acute coronary syndrome
- Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine
- 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- Risk of incident diabetes among patients treated with statins: population based study
- Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review
- Rates of hemorrhage during warfarin therapy for atrial fibrillation
- Impact of Proton Pump Inhibitor Therapy on the Efficacy of Clopidogrel in the CAPRIE and CREDO Trials
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
- 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
- Drug-Drug Interactions in Cardiovascular Catheterizations and Interventions
- 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- Prescribing proton pump inhibitors with clopidogrel
- Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs
- The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven
- Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial
- Antiplatelet Therapy and Proton Pump Inhibition: Clinician Update
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
- 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions
- Asia-Pacific Working Group consensus on non-variceal upper gastrointestinal bleeding
- Pharmacodynamic Evaluation of Pantoprazole Therapy on Clopidogrel Effects: Results of a Prospective, Randomized, Crossover Study
- Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting
- 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
- Clopidogrel and Proton Pump Inhibitors: Influence of Pharmacological Interactions on Clinical Outcomes and Mechanistic Explanations
- Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention: An Analysis From the Guthrie Health Off-Label Stent (GHOST) Investigators
- Clopidogrel-Drug Interactions
- The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers
- Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry
- CYP2C19 Genotype and Proton Pump Inhibitors in Clopidogrel-Treated Patients: Does It Take Two to Tango?
- Calcium-Channel Blockers Do Not Alter the Clinical Efficacy of Clopidogrel After Myocardial Infarction: A Nationwide Cohort Study
- The Safety of Proton Pump Inhibitors and Clopidogrel in Patients After Stroke
- Coprescription of clopidogrel and proton pump inhibitors
- Pharmacodynamic Effects of Concomitant Versus Staggered Clopidogrel and Omeprazole Intake: Results of a Prospective Randomized Crossover Study
- Comparative Effectiveness And Personalized Medicine: Evolving Together Or Apart?
- Responding to the Clopidogrel Warning by the US Food and Drug Administration: Real Life Is Complicated
- Patients With Previous Definite Stent Thrombosis Have a Reduced Antiplatelet Effect of Aspirin and a Larger Fraction of Immature Platelets
- Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration: A Systematic Meta-Analysis
- Triple Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Stents
- Minimizing the Risks of Anticoagulants and Platelet Inhibitors
- Incidence, Predictors, and Prognostic Implications of Hospitalization for Late Bleeding After Percutaneous Coronary Intervention for Patients Older Than 65 Years
- Anti-thrombotic medications for the neurointerventionist: aspirin and clopidogrel
- The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
- Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary Syndrome
- Proton Pump Inhibitors and Clopidogrel: Putting the Interaction in Perspective
- 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- Review of recent evidence: Potential interaction between clopidogrel and proton pump inhibitors
- 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
- Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose: The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study
- Cardiovascular Effects of Noncardiovascular Drugs
- Interaction between clopidogrel and proton pump inhibitors
- Interaction between clopidogrel and proton pump inhibitors
- Interaction between clopidogrel and proton pump inhibitors
- More on proton pump inhibitors
- Authors' reply
- Clopidogrel and the Concept of High-Risk Pharmacokinetics
- The drug-drug interaction between proton pump inhibitors and clopidogrel